Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Monsanto Company and Complix NV Sign Collaboration

Published: Friday, September 21, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Collaboration agreement to develop Complix’s proprietary Alphabody® protein technology in the field of agriculture.

Monsanto Company and Complix NV have announced that they have entered into a collaboration agreement to evaluate and develop Complix’s proprietary Alphabody® protein technology in the field of agriculture.

Complix is a biopharmaceutical company focused on the discovery and development of its Alphabody® technology platform.

Alphabodies are a unique class of protein therapeutics that are potentially active against a broad range of disease targets, including intracellular targets.

Alphabodies are small single chain alpha-helical proteins that are designed by computer modelling, but are inspired by naturally existing protein structures. This collaboration represents the first application of Complix’s Alphabody® technology in agriculture.

“Complix’s expertise in protein targeting technology offers a novel platform to further enhance our trait development capabilities,” said Bob Reiter, Monsanto’s Vice President of Biotechnology.

Reiter continued, “We believe this technology offers great promise and could contribute to development of new traits to protect plants from pests and diseases. We are pleased to work with Complix to develop this promising technology in a way that might deliver on-farm benefits to our grower customers.”

Under the terms of the agreement, Complix will grant Monsanto worldwide exclusive rights to access Complix’s Alphabody® platform technology for use in plant agriculture.

Complix retains the exclusive rights on any discoveries made under this collaboration for use outside the field of plant agriculture.

The agreement also includes options to expand the collaboration across multiple applications within plant agriculture. Further terms were not disclosed.

“We are delighted to have concluded this agreement with Monsanto, a leading agricultural company with a strong track record of delivering innovations to the marketplace,” said Mark Vaeck, Chief Executive Officer of Complix NV.

Vaeck continued, “By working with Monsanto, our partner of choice for this space, I am confident that we will be able to apply our Alphabody platform to address some of the most important challenges facing agriculture today and tomorrow. This strategic alliance, will also enable us to create significant value for our shareholders as it will contribute to further strengthening and expanding our Alphabody platform and help Complix to establish its leadership position in the field of cross-over therapeutics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Grant to Fund Million Peaks Project
The European Research Council (ERC) has awarded a prestigious Advanced Grant to Prof. Peter Schoenmakers, Prof. Albert Polman and Prof. Huib Bakker, all three of whom work at the University of Amsterdam (UvA).
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!